DIFICLIR (fidaxomicin) - Clostridium difficile infection

the Committee deems that the clinical benefit of DIFICLIR (fidaxomicin) 200 mg film-coated tablets remains substantial in the MA indication.

The introduction of an alternative dosing regimen (extended-pulsed dosing) does not modify the previous conclusions of the Transparency Committee (CT). The Committee considers that DIFICLIR (fidaxomicin) 200 mg film-coated tablets maintains a moderate clinical added value (CAV III) in the treatment of C. difficile infections.